Overview

NeoVax With Nivolumab in Patients With Ovarian Cancer

Status:
Recruiting

Trial end date:
2028-04-30

Target enrollment:

Participant gender:

Summary

This research study is evaluating a new type of vaccine called "Personalized NeoAntigen Cancer Vaccine" in combination with Nivolumab (Opdivo®) for ovarian cancer.

Phase:

Phase 1

Details

Lead Sponsor:

Dana-Farber Cancer Institute

Collaborator:

United States Department of Defense

Treatments:

Nivolumab